MUMBAI, India & SHORT HILLS, N.J., May 30, 2026
Wockhardt has achieved a historic milestone with the U.S. Food and Drug Administration (FDA) approval of ZAYNICH™ (cefepime and zidebactam), a novel intravenous antibiotic developed for the treatment of adults with complicated urinary tract infections (cUTIs), including pyelonephritis, caused by susceptible Gram-negative pathogens. The approval marks a significant advancement in the global fight against antimicrobial resistance (AMR) and establishes ZAYNICH as the first New Chemical Entity fully discovered, developed, and commercialized by an Indian pharmaceutical company to receive FDA approval. The innovative antibiotic combines the fourth-generation cephalosporin cefepime with zidebactam, creating a unique multi-target antibacterial therapy designed to combat some of the most challenging multidrug-resistant bacterial infections facing healthcare systems worldwide.
Phase 3 ENHANCE-1 Trial Delivers Superior Clinical Outcomes
The FDA approval was supported by results from the pivotal Phase 3 ENHANCE-1 clinical trial, a randomized, double-blind, multicenter study involving 530 hospitalized patients across 64 clinical sites in the United States, Europe, Latin America, China, and India. The study compared ZAYNICH with meropenem, one of the current standards of care for complicated urinary tract infections.
Results demonstrated a remarkable 89.0% combined clinical cure and microbiological response rate, significantly outperforming meropenem, which achieved a response rate of 68.4%. The treatment difference of 20.6 percentage points highlighted the potential of ZAYNICH to transform treatment strategies for serious Gram-negative bacterial infections. Importantly, the therapy was generally well tolerated, with the most commonly reported adverse reactions including diarrhea, hypertension, headache, and hypokalemia. These findings reinforce the potential of ZAYNICH as a critical new weapon against increasingly resistant bacterial pathogens.
Novel Multi-PBP Targeting Mechanism Addresses Antimicrobial Resistance
Advertisement
One of the most significant scientific aspects of ZAYNICH is its innovative mechanism of action. Unlike many currently available beta-lactam antibiotic combinations, ZAYNICH simultaneously targets multiple penicillin-binding proteins (PBP1a/b, PBP2, and PBP3), enabling broad-spectrum bactericidal activity against highly resistant Gram-negative organisms. Cefepime primarily targets PBP3 and PBP1a/b, while zidebactam selectively binds to PBP2, creating a synergistic antibacterial effect.
This multi-target strategy allows the antibiotic to remain active even in the presence of difficult-to-treat resistance mechanisms, including metallo-beta-lactamases (MBLs), hyper-efflux pumps, and porin channel alterations. As antimicrobial resistance continues to escalate globally, the approval of a therapy capable of overcoming multiple resistance pathways is viewed as a major advancement for infectious disease management. With more than 2.8 million antimicrobial-resistant infections occurring annually in the United States, resulting in over 35,000 deaths each year, the need for innovative antibiotics has never been greater.
Landmark Achievement for Wockhardt and Global Infectious Disease Care
The FDA approval of ZAYNICH represents not only a major commercial and scientific achievement for Wockhardt but also a significant milestone for the broader pharmaceutical industry in India. The antibiotic previously received Priority Review, Fast Track, and Qualified Infectious Disease Product (QIDP) designations from the FDA, reflecting its potential to address urgent public health challenges. The therapy has already received regulatory approval from India’s Drugs Controller General and is currently under review by the European Medicines Agency. Wockhardt’s growing anti-infective pipeline includes six antibiotics targeting both Gram-negative and Gram-positive pathogens, all of which have received QIDP designation from the FDA.
As healthcare systems worldwide continue to confront the growing burden of antimicrobial resistance, the approval of ZAYNICH provides clinicians with a powerful new treatment option and reinforces the importance of sustained innovation in anti-infective drug development. The achievement is expected to strengthen global efforts to preserve the effectiveness of antibacterial therapies while improving outcomes for patients suffering from serious and potentially life-threatening infections.
Source: Wockhardt press release
